
CPHI & PMEC China 2026
06/2026 – 06/2026
Shanghai Jinhe Bio-Pharmaceutical Co., Ltd. is a pharmaceutical enterprise dedicated to R&D, manufacturing and marketing anti-cancer APIs and their intermediates, having successfully developed Paclitaxel, Docetaxel, Irinotecan, Etoposide, Cabazitaxel and Palonosetron hydrochloride, among others. In January 2017, the company achieved GMP certification for bulk drugs Paclitaxel and Docetaxel.

Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen